Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

C M Wischik

Showing results (21-30 of 53) with videos related to

Pageof 6
Sort By:
Dementia (Basel, Switzerland)|March 1, 1996
Alterations in tau protein metabolism during normal agingE B Mukaetova-Ladinska, C R Harrington, M Roth, et al.
Journal of Neuroscience Research|August 15, 1994
Presence of axonal paired helical filament-tau in Alzheimer's disease: submicroscopic localizationW Bondareff, C R Harrington, S W McDaniel, et al.
Proceedings of the National Academy of Sciences of the United States of America|June 1, 1988
Cloning and sequencing of the cDNA encoding a core protein of the paired helical filament of Alzheimer disease: identification as the microtubule-associated protein tauM Goedert, C M Wischik, R A Crowther, et al.
Journal of Neuropathology and Experimental Neurology|September 1, 1995
Absence of abnormal hyperphosphorylation of tau in intracellular tangles in Alzheimer's diseaseW Bondareff, C R Harrington, C M Wischik, et al.
The American Journal of Pathology|September 1, 1990
Molecular analysis of neurofibrillary degeneration in Alzheimer's disease. An immunohistochemical studyW Bondareff, C M Wischik, M Novak, et al.
Neuroreport|November 1, 1990
Normal densities of 5-HT3 receptor recognition sites in Alzheimer's diseaseN M Barnes, B Costall, R J Naylor, et al.
Journal of Chemical Neuroanatomy|July 27, 2001
Accumulation of C-terminally truncated tau protein associated with vulnerability of the perforant pathway in early stages of neurofibrillary pathology in Alzheimer's diseaseF García-Sierra, C M Wischik, C R Harrington, et al.
Biochimica Et Biophysica Acta|October 3, 1993
Characterisation of an epitope specific to the neuron-specific isoform of human enolase recognised by a monoclonal antibody raised against a synthetic peptide corresponding to the C-terminus of beta/A4-proteinC R Harrington, G B Quinn, J Hurt, et al.
Proceedings of the National Academy of Sciences of the United States of America|October 1, 1996
Selective inhibition of Alzheimer disease-like tau aggregation by phenothiazinesC M Wischik, P C Edwards, R Y Lai, et al.
The Journal of Prevention of Alzheimer'S Disease|October 25, 2022
Oral Tau Aggregation Inhibitor for Alzheimer's Disease: Design, Progress and Basis for Selection of the 16 mg/day Dose in a Phase 3, Randomized, Placebo-Controlled Trial of Hydromethylthionine MesylateC M Wischik, P Bentham, S Gauthier, et al.
Pageof 6

Showing results (21-30 of 53) with videos related to

Sort By:
Pageof 6
Dementia (Basel, Switzerland)|March 1, 1996
Alterations in tau protein metabolism during normal agingE B Mukaetova-Ladinska, C R Harrington, M Roth, et al.
Journal of Neuroscience Research|August 15, 1994
Presence of axonal paired helical filament-tau in Alzheimer's disease: submicroscopic localizationW Bondareff, C R Harrington, S W McDaniel, et al.
Proceedings of the National Academy of Sciences of the United States of America|June 1, 1988
Cloning and sequencing of the cDNA encoding a core protein of the paired helical filament of Alzheimer disease: identification as the microtubule-associated protein tauM Goedert, C M Wischik, R A Crowther, et al.
Journal of Neuropathology and Experimental Neurology|September 1, 1995
Absence of abnormal hyperphosphorylation of tau in intracellular tangles in Alzheimer's diseaseW Bondareff, C R Harrington, C M Wischik, et al.
The American Journal of Pathology|September 1, 1990
Molecular analysis of neurofibrillary degeneration in Alzheimer's disease. An immunohistochemical studyW Bondareff, C M Wischik, M Novak, et al.
Neuroreport|November 1, 1990
Normal densities of 5-HT3 receptor recognition sites in Alzheimer's diseaseN M Barnes, B Costall, R J Naylor, et al.
Journal of Chemical Neuroanatomy|July 27, 2001
Accumulation of C-terminally truncated tau protein associated with vulnerability of the perforant pathway in early stages of neurofibrillary pathology in Alzheimer's diseaseF García-Sierra, C M Wischik, C R Harrington, et al.
Biochimica Et Biophysica Acta|October 3, 1993
Characterisation of an epitope specific to the neuron-specific isoform of human enolase recognised by a monoclonal antibody raised against a synthetic peptide corresponding to the C-terminus of beta/A4-proteinC R Harrington, G B Quinn, J Hurt, et al.
Proceedings of the National Academy of Sciences of the United States of America|October 1, 1996
Selective inhibition of Alzheimer disease-like tau aggregation by phenothiazinesC M Wischik, P C Edwards, R Y Lai, et al.
The Journal of Prevention of Alzheimer'S Disease|October 25, 2022
Oral Tau Aggregation Inhibitor for Alzheimer's Disease: Design, Progress and Basis for Selection of the 16 mg/day Dose in a Phase 3, Randomized, Placebo-Controlled Trial of Hydromethylthionine MesylateC M Wischik, P Bentham, S Gauthier, et al.
Pageof 6